Companie's Offerings in the Colorectal Cancer Diagnostics Market
Everything you need to track the Colorectal Cancer Diagnostics Market, organized in one intelligent view - Download for Free.
| Company | Description |
| Exact Sciences Corporation | This firm specializes in non-invasive colorectal cancer screening & molecular diagnostics. |
| F. Hoffmann-La Roche Ltd (Roche Diagnostics) | Its portfolio covers integration of in vitro diagnostics (IVD), next-generation sequencing (NGS), & digital health solutions. |
| Quest Diagnostics Incorporated | This company offers various blood-based screening, fecal testing, & sophisticated molecular diagnostics. |
| Danaher Corporation | This mainly facilitates tissue staining for diagnosis, molecular testing for biomarkers, & 3D biology technologies for drug discovery. |
| Guardant Health, Inc. | Its offerings cover the FDA-approved Shield test & Guardant Reveal. |
| Abbott | This leader explored Cologuard & Cologuard Plus to their lineup, with existing rapid fecal tests to optimize early detection. |
| Fujifilm Holdings Corporation | A firm provides AI-enabled endoscopic imaging, therapeutic devices, & specialized screening centers. |
| Epigenomics AG | Its prominent offering is blood-based molecular diagnostics for colorectal cancer. |
| Eiken Chemical Co., Ltd | This offers screening through its OC-SENSOR line of Fecal Immunochemical Tests (FIT), with emphasis on non-invasive detection of human hemoglobin in stool. |
| Olympus Corporation | It has unveiled the EVIS X1 endoscopy system with TXI technology, OLYSENSE AI-driven diagnostic software, & the Endocuff Vision device. |
What are the Recent Developments in the Colorectal Cancer Diagnostics Market?
- In January 2026, SAGA Diagnostics unveiled its ultrasensitive Pathlight MRD diagnostic test for patients with colorectal cancer (CRC).
- In October 2025, Fujifilm Healthcare Americas Corporation launched its advanced endoscopy platform, the ELUXEO 8000 Endoscopic Imaging System, to boost endoscopic image quality, therapeutic capabilities, & workflow efficiencies.
- In July 2025, Exact Sciences Corp. rolled out Medicare coverage for its Oncodetect molecular residual disease (MRD) test for patients with colorectal cancer.
Colorectal Cancer Diagnostics Market- Supply Chain Analysis
R&D
- Firms are following the creation of more accurate, non-invasive, & early-detection tools, including target discovery, assay development & improvement, then all preclinical & clinical studies.
- Key Players: Exact Sciences, Guardant Health, Roche Diagnostics, etc.
Regulatory Approvals
- This prominently covers 510(k) clearance for devices similar to existing ones & Premarket Approval (PMA) for novel technologies.
- Key Players: US FDA, EMA, NICE, etc.
Patient Support & Services
- The market is promoting screening, imaging, & diagnostic colonoscopies powered by counseling, financial aid, & care coordination to manage increased patient requirements.
- Key Players: Colorectal Cancer Alliance, Prevent Cancer Foundation, Apollo Hospitals, etc.
Market Growth
The global colorectal cancer diagnostics market size was estimated at USD 18.7 billion in 2025 and is predicted to increase from USD 20.36 billion in 2026 to approximately USD 43.87 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035. A gradual rise in CRC incidence & broadening awareness, with robust screening programs, are driving the demand for these diagnostics. Besides this, the market is transforming AI-assisted solutions & the latest molecular diagnostics.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking